A combined opposite targeting of p110δ PI3K and RhoA abrogates skin cancer
Niki Tzenaki(University of Crete), Evangelia A. Papakonstanti(University of Crete)
Cited by 2
Related Papers
Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages
|Journal of Cell Science|2008|94
IOA-244, a novel p110δ PI3K inhibitor, blocks breast tumour progression on either mono- or combined-therapy
|Cell Death Discovery|2026|0